SCHEDULE 13G/A: Fairmount Funds Management Divests Entire 6% Stake in AnaptysBio, Inc.

Fairmount Funds Management LLC and its affiliated entities have fully divested their 6% beneficial ownership in AnaptysBio, Inc., as reported in an amended Schedule 13G filing.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The amendment reports a complete divestment of their beneficial ownership in ANAPTYSBIO, INC.'s Common Stock.
• As of December 31, 2024, the Reporting Persons' beneficial ownership consisted of 1,816,466 shares, representing 6% of the class's shares outstanding.
• As of the filing date of this amendment (February 14, 2025), the Reporting Persons hold no shares of Common Stock in AnaptysBio, Inc., resulting in 0.0% beneficial ownership.
• Fairmount Funds Management LLC serves as the investment adviser for Fairmount Healthcare Fund II L.P., with Peter Harwin and Tomas Kiselak serving as managing members of Fairmount.

Sentiment

Score: 3

Explanation: The complete divestment of a significant stake by an institutional investor is a negative signal, indicating a lack of confidence in the company's future prospects from the perspective of the divesting entity.

Negatives

• A significant institutional investor, Fairmount Funds Management LLC, has completely divested its 6% stake in AnaptysBio, Inc., which could be interpreted as a loss of confidence in the company's future prospects by this investor.

Risks

• The complete divestment by a significant institutional holder like Fairmount Funds Management LLC could signal potential concerns about AnaptysBio, Inc.'s future performance or strategic direction, potentially leading to negative market sentiment and share price pressure.
• The reduction in institutional ownership might decrease the stock's liquidity or make it less attractive to other institutional investors.

Future Outlook

The document does not provide any forward-looking statements or guidance from AnaptysBio, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's stock, primarily for investment purposes. An amendment to a 13G, especially one indicating a complete divestment, can be a significant signal to the market regarding an investor's changing view of a company's prospects. In the biotechnology sector, such divestments by specialized healthcare funds can be particularly scrutinized given the industry's reliance on investor confidence and capital.

Stakeholder Impact

• Shareholders: The divestment by a significant institutional investor could lead to negative market sentiment, potentially impacting the share price and overall investor confidence in AnaptysBio, Inc.

Key Dates

Recommendation

Keywords

AnaptysBio, Fairmount Funds Management, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, biotechnology, SEC filing